150 related articles for article (PubMed ID: 37388683)
1. Polyvalent Nano-Lectin Potently Neutralizes SARS-CoV-2 by Targeting Glycans on the Viral Spike Protein.
Budhadev D; Hooper J; Rocha C; Nehlmeier I; Kempf AM; Hoffmann M; Krüger N; Zhou D; Pöhlmann S; Guo Y
JACS Au; 2023 Jun; 3(6):1755-1766. PubMed ID: 37388683
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Select SARS-CoV-2 N-Linked Glycan and Variant of Concern Spike Protein Mutations on C-Type Lectin-Receptor-Mediated Infection.
Bains A; Guan W; LiWang PJ
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766307
[TBL] [Abstract][Full Text] [Related]
3. Lentil lectin derived from
Wang W; Li Q; Wu J; Hu Y; Wu G; Yu C; Xu K; Liu X; Wang Q; Huang W; Wang L; Wang Y
Emerg Microbes Infect; 2021 Dec; 10(1):1519-1529. PubMed ID: 34278967
[TBL] [Abstract][Full Text] [Related]
4. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
[TBL] [Abstract][Full Text] [Related]
5. Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.
Vanhulle E; D'huys T; Provinciael B; Stroobants J; Camps A; Noppen S; Schols D; Van Damme EJM; Maes P; Stevaert A; Vermeire K
Front Cell Infect Microbiol; 2022; 12():989534. PubMed ID: 36111239
[No Abstract] [Full Text] [Related]
6. Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants.
Li J; Liu Q; Liu J; Fang Z; Luo L; Li S; Lei Y; Li Z; Jin J; Xie R; Peng Y
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366316
[TBL] [Abstract][Full Text] [Related]
7. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
8. Characterization and Function of Glycans on the Spike Proteins of SARS-CoV-2 Variants of Concern.
Zheng L; Wang K; Chen M; Qin F; Yan C; Zhang XE
Microbiol Spectr; 2022 Dec; 10(6):e0312022. PubMed ID: 36318020
[TBL] [Abstract][Full Text] [Related]
9. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menacherry V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
bioRxiv; 2022 Mar; ():. PubMed ID: 33972947
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
11. Site Specific N- and O-glycosylation mapping of the Spike Proteins of SARS-CoV-2 Variants of Concern.
Shajahan A; Pepi L; Kumar B; Murray N; Azadi P
Res Sq; 2022 Nov; ():. PubMed ID: 36415454
[TBL] [Abstract][Full Text] [Related]
12.
Pandey AK; Verma S
Drug Dev Ind Pharm; 2022 Oct; 48(10):539-551. PubMed ID: 36250723
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
Kim CH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein.
Zhang S; Go EP; Ding H; Anang S; Kappes JC; Desaire H; Sodroski JG
J Virol; 2022 Feb; 96(3):e0162621. PubMed ID: 34817202
[TBL] [Abstract][Full Text] [Related]
15. Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.
Agudelo M; Muecksch F; Schaefer-Babajew D; Cho A; DaSilva J; Bednarski E; Ramos V; Oliveira TY; Cipolla M; Gazumyan A; Zong S; Rodrigues DAS; Lira GS; Conde L; Aguiar RS; Ferreira OC; Tanuri A; Affonso KC; Galliez RM; Castineiras TMPP; Echevarria-Lima J; Bozza MT; Vale AM; Bieniasz PD; Hatziioannou T; Nussenzweig MC
J Exp Med; 2022 Sep; 219(9):. PubMed ID: 35796685
[TBL] [Abstract][Full Text] [Related]
16. An antibody from single human V
Luo S; Zhang J; Kreutzberger AJB; Eaton A; Edwards RJ; Jing C; Dai HQ; Sempowski GD; Cronin K; Parks R; Ye AY; Mansouri K; Barr M; Pishesha N; Williams AC; Vieira Francisco L; Saminathan A; Peng H; Batra H; Bellusci L; Khurana S; Alam SM; Montefiori DC; Saunders KO; Tian M; Ploegh H; Kirchhausen T; Chen B; Haynes BF; Alt FW
Sci Immunol; 2022 Oct; 7(76):eadd5446. PubMed ID: 35951767
[TBL] [Abstract][Full Text] [Related]
17. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants.
Westendorf K; Žentelis S; Wang L; Foster D; Vaillancourt P; Wiggin M; Lovett E; van der Lee R; Hendle J; Pustilnik A; Sauder JM; Kraft L; Hwang Y; Siegel RW; Chen J; Heinz BA; Higgs RE; Kallewaard NL; Jepson K; Goya R; Smith MA; Collins DW; Pellacani D; Xiang P; de Puyraimond V; Ricicova M; Devorkin L; Pritchard C; O'Neill A; Dalal K; Panwar P; Dhupar H; Garces FA; Cohen CA; Dye JM; Huie KE; Badger CV; Kobasa D; Audet J; Freitas JJ; Hassanali S; Hughes I; Munoz L; Palma HC; Ramamurthy B; Cross RW; Geisbert TW; Menachery V; Lokugamage K; Borisevich V; Lanz I; Anderson L; Sipahimalani P; Corbett KS; Yang ES; Zhang Y; Shi W; Zhou T; Choe M; Misasi J; Kwong PD; Sullivan NJ; Graham BS; Fernandez TL; Hansen CL; Falconer E; Mascola JR; Jones BE; Barnhart BC
Cell Rep; 2022 May; 39(7):110812. PubMed ID: 35568025
[TBL] [Abstract][Full Text] [Related]
18. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
19. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope.
Wang X; Chen X; Tan J; Yue S; Zhou R; Xu Y; Lin Y; Yang Y; Zhou Y; Deng K; Chen Z; Ye L; Zhu Y
Cell Host Microbe; 2022 Jun; 30(6):887-895.e4. PubMed ID: 35436443
[TBL] [Abstract][Full Text] [Related]
20. Dissecting Multivalent Lectin-Carbohydrate Recognition Using Polyvalent Multifunctional Glycan-Quantum Dots.
Guo Y; Nehlmeier I; Poole E; Sakonsinsiri C; Hondow N; Brown A; Li Q; Li S; Whitworth J; Li Z; Yu A; Brydson R; Turnbull WB; Pöhlmann S; Zhou D
J Am Chem Soc; 2017 Aug; 139(34):11833-11844. PubMed ID: 28786666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
